Colorectal Cancer

Deficiency in the protein NOD-like receptor X1 (NLRX1) could represent a potential biomarker to predict response to therapies in patients with colorectal cancer.

Zsofia K. Stadler, MD, provides extensive insight on microsatellite instability in colorectal cancer, the biology of and screening for MSI tumors, and the potential impact immunotherapy could have on the treatment paradigm.

Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer without contributing significant toxicity.

Many patients with metastatic colorectal cancer will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

Jennifer Wu, MD, reviews recently approved agents in refractory colorectal cancer, as well as biomarker-directed emerging therapies in the setting.

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

Experts in the field assert that the path forward requires a paradigm shift toward integrative analyses that encompass multiple classes of genomic aberrations and consensus classification of CRC based on genomic data to facilitate more effective management of this disease.